​
​

Inhibikase Therapeutics (IKT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

IKT Stock Forecast

Inhibikase Therapeutics stock forecast is as follows: an average price target of $6.50 (represents a 228.28% upside from IKT’s last price of $1.98) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

IKT Price Target

The average price target for Inhibikase Therapeutics (IKT) is $6.50 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $8.00 to $5.00. This represents a potential 228.28% upside from IKT's last price of $1.98.

IKT Analyst Ratings

Buy

According to 3 Wall Street analysts, Inhibikase Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for IKT stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Inhibikase Therapeutics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 08, 2024Dennis DingJefferies$8.00$2.78187.77%304.04%
Oct 11, 2024Edward WhiteH.C. Wainwright$5.00$1.42252.09%152.53%
Row per page
Go to

The latest Inhibikase Therapeutics stock forecast, released on Nov 08, 2024 by Dennis Ding from Jefferies, set a price target of $8.00, which represents a 187.77% increase from the stock price at the time of the forecast ($2.78), and a 304.04% increase from IKT last price ($1.98).

Inhibikase Therapeutics Price Target by Period

1M3M12M
# Anlaysts122
Avg Price Target$8.00$6.50$6.50
Last Closing Price$1.98$1.98$1.98
Upside/Downside304.04%228.28%228.28%

In the current month, the average price target of Inhibikase Therapeutics stock is $8.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 304.04% increase as opposed to Inhibikase Therapeutics's last price of $1.98. This month's average price target is up 23.08% compared to last quarter, and up 23.08% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 08, 2024Jefferies-BuyInitialise
Oct 11, 2024H.C. WainwrightBuyBuyHold
Aug 16, 2024H.C. WainwrightBuyBuyHold
May 21, 2024H.C. WainwrightBuyBuyHold
Nov 16, 2022JonesTrading-HoldDowngrade
Row per page
Go to

Inhibikase Therapeutics's last stock rating was published by Jefferies on Nov 08, 2024. The company Initialise its IKT rating from "null" to "Buy".

Inhibikase Therapeutics Financial Forecast

Inhibikase Therapeutics Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21
Revenue-----------$7.29K$6.55K-$1.94K$328.46K$1.36M
Avg Forecast-----------$200.00K$300.00K$300.00K$300.00K$200.00K$300.00K
High Forecast-----------$200.00K$300.00K$300.00K$300.00K$200.00K$300.00K
Low Forecast-----------$200.00K$300.00K$300.00K$300.00K$200.00K$300.00K
# Analysts-----------111111
Surprise %-----------0.04%0.02%-0.01%1.64%4.54%

Inhibikase Therapeutics's average Quarter revenue forecast for Jun 24 based on 0 analysts is -, with a low forecast of -, and a high forecast of -. IKT's average Quarter revenue forecast represents a -100.00% decrease compared to the company's last Quarter revenue of $7.29K (Sep 22).

Inhibikase Therapeutics EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21
# Analysts-----------111111
EBITDA-----------$-4.49M$-4.64M$-4.64M$-5.04M$-4.47M$-2.63M
Avg Forecast-----------$-200.00K$-300.00K$-4.37M$-300.00K$-3.19M$-300.00K
High Forecast-----------$-200.00K$-300.00K$-3.49M$-300.00K$-2.56M$-300.00K
Low Forecast-----------$-200.00K$-300.00K$-5.24M$-300.00K$-3.83M$-300.00K
Surprise %-----------22.47%15.47%1.06%16.80%1.40%8.76%

undefined analysts predict IKT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Inhibikase Therapeutics's previous annual EBITDA (undefined) of $NaN.

Inhibikase Therapeutics Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21
# Analysts-----------111111
Net Income-----------$-4.46M$-4.64M$-4.64M$-5.04M$-4.47M$-2.64M
Avg Forecast$-1.87M$-1.07M$-1.07M$-977.08K$-1.33M$-1.24M$-1.07M$-977.08K$-769.83K$-4.26M$-5.05M$-8.14M$-8.59M$-4.37M$-7.69M$-3.19M$-17.18M
High Forecast$-1.87M$-1.07M$-1.07M$-977.08K$-1.33M$-1.24M$-1.07M$-977.08K$-692.84K$-4.26M$-5.05M$-8.14M$-8.59M$-3.49M$-7.69M$-2.55M$-17.18M
Low Forecast$-1.87M$-1.07M$-1.07M$-977.08K$-1.33M$-1.24M$-1.07M$-977.08K$-769.83K$-4.26M$-5.05M$-8.14M$-8.59M$-5.24M$-7.69M$-3.83M$-17.18M
Surprise %-----------0.55%0.54%1.06%0.66%1.40%0.15%

Inhibikase Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. IKT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Inhibikase Therapeutics SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21
# Analysts-----------111111
SG&A-----------$1.54M$1.66M$1.67M$1.65M$1.64M$1.61M
Avg Forecast-----------$3.43M$5.15M$5.15M$5.15M$3.43M$5.15M
High Forecast-----------$3.43M$5.15M$5.15M$5.15M$3.43M$5.15M
Low Forecast-----------$3.43M$5.15M$5.15M$5.15M$3.43M$5.15M
Surprise %-----------0.45%0.32%0.32%0.32%0.48%0.31%

Inhibikase Therapeutics's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to IKT last annual SG&A of $1.54M (Sep 22).

Inhibikase Therapeutics EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21
# Analysts-----------111111
EPS-----------$-0.18$-0.18$-0.18$-0.20$-0.18$-0.22
Avg Forecast$-0.21$-0.12$-0.12$-0.11$-0.15$-0.14$-0.12$-0.11$-0.09$-0.48$-0.67$-1.08$-1.14$-1.02$-1.02$-0.84$-2.28
High Forecast$-0.21$-0.12$-0.12$-0.11$-0.15$-0.14$-0.12$-0.11$-0.08$-0.48$-0.67$-1.08$-1.14$-1.02$-1.02$-0.84$-2.28
Low Forecast$-0.21$-0.12$-0.12$-0.11$-0.15$-0.14$-0.12$-0.11$-0.09$-0.48$-0.67$-1.08$-1.14$-1.02$-1.02$-0.84$-2.28
Surprise %-----------0.17%0.16%0.18%0.20%0.21%0.10%

According to undefined Wall Street analysts, Inhibikase Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to IKT previous annual EPS of $NaN (undefined).

Inhibikase Therapeutics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
PMVPPMV Pharmaceuticals$1.57$18.001046.50%Buy
ANTXAN2 Therapeutics$1.30$8.75573.08%Buy
LIFEaTyr Pharma$1.90$11.00478.95%Buy
LGVNLongeveron$1.85$10.00440.54%Buy
MISTMilestone Pharmaceuticals$1.86$10.00437.63%Buy
ANEBAnebulo Pharmaceuticals$1.52$6.00294.74%Buy
IKTInhibikase Therapeutics$1.98$6.50228.28%Buy
DMACDiaMedica Therapeutics$4.02$8.33107.21%Buy
MCRBSeres Therapeutics$0.81$1.2554.32%Buy

IKT Forecast FAQ

Is Inhibikase Therapeutics a good buy?

Yes, according to 3 Wall Street analysts, Inhibikase Therapeutics (IKT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of IKT's total ratings.

What is IKT's price target?

Inhibikase Therapeutics (IKT) average price target is $6.5 with a range of $5 to $8, implying a 228.28% from its last price of $1.98. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Inhibikase Therapeutics stock go up soon?

According to Wall Street analysts' prediction for IKT stock, the company can go up by 228.28% (from the last price of $1.98 to the average price target of $6.5), up by 304.04% based on the highest stock price target, and up by 152.53% based on the lowest stock price target.

Can Inhibikase Therapeutics stock reach $3?

IKT's average twelve months analyst stock price target of $6.5 supports the claim that Inhibikase Therapeutics can reach $3 in the near future.

What is Inhibikase Therapeutics's current price target trend?

1 Wall Street analyst forecast a $8 price target for Inhibikase Therapeutics (IKT) this month, up 304.04% from its last price of $1.98. Compared to the last 3 and 12 months, the average price target increased by 228.28% and increased by 228.28%, respectively.

What are Inhibikase Therapeutics's analysts' financial forecasts?

Inhibikase Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-4.619M (high $-4.619M, low $-4.619M), average SG&A $0 (high $0, low $0), and average EPS is $-0.52 (high $-0.52, low $-0.52). IKT's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-4.974M (high $-4.974M, low $-4.974M), average SG&A $0 (high $0, low $0), and average EPS is $-0.56 (high $-0.56, low $-0.56).

Did the IKT's actual financial results beat the analysts' financial forecasts?

Based on Inhibikase Therapeutics's last annual report (Dec 2021), the company's revenue was $3.1M, beating the average analysts forecast of $800K by 287.58%. Apple's EBITDA was $-14.766M, beating the average prediction of $-3.794M by 289.22%. The company's net income was $-14.786M, missing the average estimation of $-28.061M by -47.31%. Apple's SG&A was $6.51M, missing the average forecast of $13.74M by -52.63%. Lastly, the company's EPS was $-0.81, missing the average prediction of $-4.14 by -80.43%. In terms of the last quarterly report (Sep 2022), Inhibikase Therapeutics's revenue was $7.29K, missing the average analysts' forecast of $200K by -96.35%. The company's EBITDA was $-4.495M, beating the average prediction of $-200K by 2147.28%. Inhibikase Therapeutics's net income was $-4.457M, missing the average estimation of $-8.139M by -45.23%. The company's SG&A was $1.54M, missing the average forecast of $3.43M by -55.20%. Lastly, the company's EPS was $-0.18, missing the average prediction of $-1.08 by -83.33%